TEMSO phase III study results for relapsing MS
TEMSO phase III study results for relapsing MS
Sanofi-aventis announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS).
In this study, both doses of teriflunomide (7 and 14mg) significantly reduced annualized relapse rate (primary study endpoint) by 31% vs. placebo (p is less than or equal to 0.0005). The risk of disability progression (sustained for 12 weeks) was also significantly reduced by 30% for the 14mg dose... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 2 Replies
- 1199 Views
-
Last post by David1949
-
- 0 Replies
- 1314 Views
-
Last post by frodo
-
- 0 Replies
- 1727 Views
-
Last post by NHE
-
- 2 Replies
- 4371 Views
-
Last post by DIM
-
- 1 Replies
- 3167 Views
-
Last post by Tif
-
- 0 Replies
- 2512 Views
-
Last post by NHE
-
- 1 Replies
- 1244 Views
-
Last post by Scott1
-
- 1 Replies
- 1942 Views
-
Last post by frodo
-
- 0 Replies
- 2013 Views
-
Last post by DIM